| scholarly article | Q13442814 |
| P2093 | author name string | Arakawa T | |
| Goldwasser E | |||
| Everett R | |||
| Lai PH | |||
| Wang FF | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 3116-3121 | |
| P577 | publication date | 1986-03-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Structural characterization of human erythropoietin | |
| P478 | volume | 261 |
| Q62223739 | A synthetic approach to 'click' neoglycoprotein analogues of EPO employing one-pot native chemical ligation and CuAAC chemistry |
| Q41761661 | Amino acid distributions around O-linked glycosylation sites |
| Q41439145 | An advance in the chemical synthesis of homogeneous N-linked glycopolypeptides by convergent aspartylation |
| Q30369721 | C-Terminally fused affinity Strep-tag II is removed by proteolysis from recombinant human erythropoietin expressed in transgenic tobacco plants. |
| Q99551051 | Carbamylated erythropoietin regulates immune responses and promotes long-term kidney allograft survival through activation of PI3K/AKT signaling |
| Q37627225 | Carbohydrate analysis throughout the development of a protein therapeutic |
| Q37533151 | Cardiovascular Effects of Erythropoietin |
| Q46567387 | Changes in conformation and stability upon formation of complexes of erythropoietin (EPO) and soluble EPO receptor |
| Q36322453 | Convergent chemical synthesis of [lysine(24,38,83)] human erythropoietin |
| Q28362976 | Development and characterization of novel erythropoiesis stimulating protein (NESP) |
| Q38900773 | Development of a VHH-Based Erythropoietin Quantification Assay |
| Q30399757 | Development of an in vitro Bioassay for Recombinant Human Erythropoietin (rHuEPO) Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Sialic Acid Dependent Microheterogeneity: UT-7 Cell Bioassay. |
| Q57665964 | Direct quality control of glycoengineered erythropoietin variants |
| Q37686245 | Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact |
| Q46941601 | Dynamic control of oligosaccharide modification in the mammary gland: linking recombinant human erythropoietin functional analysis of transgenic mouse milk-derived hEPO. |
| Q42003728 | EV-3, an endogenous human erythropoietin isoform with distinct functional relevance |
| Q27333474 | Encapsulation-free controlled release: Electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles |
| Q38172120 | Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives |
| Q34488415 | Erythropoietin and cancer: the unintended consequences of anemia correction |
| Q35909929 | Erythropoietin in brain development and beyond |
| Q37334021 | Erythropoietin in spinal cord injury |
| Q24240202 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data |
| Q34100489 | Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system |
| Q37912819 | Erythropoietin: an old friend revisited |
| Q42797884 | Erythropoietin: recent developments in the treatment of spinal cord injury |
| Q70179666 | Hematopoietic growth factors |
| Q35534798 | Heterologous protein production in yeast |
| Q39450330 | Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO). |
| Q35799107 | Human erythropoietin dimers with markedly enhanced in vivo activity |
| Q42034117 | Mature Homogeneous Erythropoietin-Level Building Blocks by Chemical Synthesis: The EPO 114-166 Glycopeptide Domain, Presenting the O-Linked Glycophorin |
| Q37373969 | Native chemical ligation at valine: a contribution to peptide and glycopeptide synthesis. |
| Q34034670 | Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin |
| Q49505001 | Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress |
| Q45239759 | Overexpression of human erythropoietin (EPO) affects plant morphologies: retarded vegetative growth in tobacco and male sterility in tobacco and Arabidopsis |
| Q37104945 | Oxo-ester mediated native chemical ligation: concept and applications. |
| Q26781325 | Potential Use of Biological Proteins for Liver Failure Therapy |
| Q35982743 | Probing the stability of nonglycosylated wild-type erythropoietin protein via reiterative alanine ligations |
| Q37428099 | Recent Departures in the Synthesis of Peptides and Glycopeptides |
| Q42174090 | Recombinant human erythropoietin (rHuEPO): cross-linking with disuccinimidyl esters and identification of the interfacing domains in EPO. |
| Q36655932 | Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study |
| Q38005775 | Role of erythropoietin in adaptation to hypoxia |
| Q42603321 | Sequence and structural relationships in the cytokine family |
| Q30803499 | Study on the quality of recombinant proteins using matrix-assisted laser desorption ionization time of flight mass spectrometry |
| Q64059491 | Surface patches on recombinant erythropoietin predict protein solubility: engineering proteins to minimise aggregation |
| Q34725972 | Survival and proliferative roles of erythropoietin beyond the erythroid lineage |
| Q42704983 | The antioxidant effect of erythropoietin on thalassemic blood cells |
| Q33938752 | Toward homogeneous erythropoietin: fine tuning of the C-terminal acyl donor in the chemical synthesis of the Cys29-Gly77 glycopeptide domain |
| Q90343897 | Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach |
Search more.